Accelerating Access to Hepatitis C Diagnostics and Treatment

Globally, at the end of 2017, only 5 million – or 7% – of the 71 (62–79) million people chronically infected with HCV had cumulatively received treatment with DAAs. As countries continue to tackle the disease burden and service disruptions caused by the COVID-19 pandemic, it is critical to ensure that the recent momentum and gains in the response to hepatitis C are not lost. Against this backdrop, this report is a strong reminder to continue to invest in building resilient and sustainable health systems that are focused on universal health coverage.